Show simple item record

dc.contributor.authorVanderWeele, DJ
dc.contributor.authorAntonarakis, ES
dc.contributor.authorCarducci, MA
dc.contributor.authorDreicer, R
dc.contributor.authorFizazi, K
dc.contributor.authorGillessen, Silke
dc.contributor.authorHigano, CS
dc.contributor.authorMorgans, AK
dc.contributor.authorPetrylak, DP
dc.contributor.authorSweeney, CJ
dc.contributor.authorHussain, M
dc.date.accessioned2019-10-07T15:16:42Z
dc.date.available2019-10-07T15:16:42Z
dc.date.issued2019en
dc.identifier.citationVanderWeele DJ, Antonarakis ES, Carducci MA, Dreicer R, Fizazi K, Gillessen S, et al. Metastatic hormone-sensitive prostate cancer: clinical decision making in a rapidly evolving landscape of life-prolonging therapy. J Clin Oncol. 2019 Sep 10:JCO1901595.en
dc.identifier.pmid31498754en
dc.identifier.doi10.1200/JCO.19.01595en
dc.identifier.urihttp://hdl.handle.net/10541/622199
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.19.01595en
dc.titleMetastatic hormone-sensitive prostate cancer: clinical decision making in a rapidly evolving landscape of life-prolonging therapyen
dc.typeArticleen
dc.contributor.departmentRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago,en
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record